This site is intended for healthcare professionals
NICE has overturned its original decision to reject the rheumatoid arthritis treatment abatacept (Orencia).
In a review of its 2008 guidance, the institute has ruled that abatacept, in combination with methotrexate, can be considered for adults with severe active rheumatoid arthritis who are unresponsive or intolerant to a DMARD (including at least one TNF inhibitor) and in whom rituximab is unsuitable.
Adalimumab, etanercept and infliximab are recommended as other treatment options alongside abatacept.
Following a review, NICE have overturned their previous...
BMS has launched a prefilled syringe presentation of...
The most up-to-date drug information at your fingertips.
Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.
NICE has withdrawn its recommendation to quadruple...
Use our timeline to follow the latest coronavirus developments...
NICE has issued guidance on antibiotic choices and...
The MHRA has amended its advice relating to the long-acting...
Drugs
Conditions
News and resources
MIMS Hosted